Keʻena Honua

Ma Iulai 17, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka National Medical Products Administration (NMPA) ua ʻae kūhelu ʻia ka noi kūʻai aku no Trastuzumab Deruxtecan (Enhertu®) no ka lāʻau lapaʻau laina lua o ka maʻi ʻōpū e ka NMPA. He mea hoʻohui kēia noi...E heluhelu hou aku»

Ua hoʻolaha aku nei ʻo Ascentage Pharma ua ʻāpono ʻia kāna mea hoʻopaʻa hou Bcl-2 selective inhibitor lisaftoclax (APG-2575) e ka National Medical Products Administration (NMPA) o Kina no ka mālama ʻana i nā poʻe makua me ka leukemia lymphocytic mau/lymphoma lymphocytic liʻiliʻi (CLL/SLL)...E heluhelu hou aku»

Ua hoʻolaha aku nei ʻo GenFleet Therapeutics ua ʻae ka Pharmaceutical Administration Bureau (ISAF) o ka Macau Special Administrative Region ma Kina iā Dupert®（fulzerasib, GFH925/IBI351）no ka mālama ʻana i nā maʻi me ka maʻi ʻaʻai māmā ʻaʻole liʻiliʻi (NSCLC) e hūnā ana i ka KRAS G12C mutati...E heluhelu hou aku»

Ma Iune 30, ua loaʻa i ka mea hoʻopaʻa MET kūʻokoʻa ʻo Vebreltinib i hoʻomohala kūʻokoʻa ʻia e Avistone ka ʻae ʻia mai ka National Medical Products Administration (NMPA) o Kina no ka mālama ʻana i nā maʻi me ka maʻi kanesa māmā non-small cell (NSCLC) kūloko holomua a metastatic paha e hūnā ana i ka MET amplifi...E heluhelu hou aku»

Ma Iune 30, 2025, hoʻolaha ʻo HUTCHMED ua ʻae ʻia ka New Drug Application (NDA) no ka hui pū ʻana o ORPATHYS (savolitinib) a me TAGRISSO (osimertinib) e ka China National Medical Products Administration (NMPA) no ka mālama ʻana i nā maʻi me ka holomua kūloko a i ʻole metastati...E heluhelu hou aku»

Ma Iune 30, ua hoʻolaha ka pūnaewele kūhelu o ka National Medical Products Administration (NMPA) ua loaʻa iā Anlotinib, kahi lāʻau lapaʻau hou Class 1 i hoʻomohala ʻia e Chia Tai Tianqing, ka ʻae ʻia no kahi hōʻailona hou ma Kina: ka hui pū ʻana me ka chemotherapy no ka mālama mua ʻana o nā maʻi ...E heluhelu hou aku»

Ma Iune 26, 2025, hoʻolaha ʻo CARsgen ua ʻae ka National Medical Products Administration (NMPA) o Kina i ka New Drug Application (NDA) no ka satricabtagene autoleucel (“satri-cel”, CT041) (he moho huahana CAR T-cell autologous e kūʻē i ka protein Claudin18.2) no ka mālama ʻana iā Claudi...E heluhelu hou aku»

Ma Iune 19, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka National Medical Products Administration (NMPA) ua hāpai ʻia ka injection LM-108 a Livzon Pharmaceutical no ka hoʻokomo ʻia ʻana i loko o ka hoʻolālā lapaʻau holomua. ʻO ka hui pū ʻana o ka injection antibody monoclonal Kefeqibai (LM-1...E heluhelu hou aku»

Ma Iune 19, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka National Medical Products Administration (NMPA) ua hāpai ʻia ʻo Innovent Biologics' IBI343 no ka hoʻokomo ʻia ʻana i loko o ka papahana hoʻolālā lapaʻau holomua, i manaʻo ʻia no ka mālama ʻana i ka pan holomua kūloko a i ʻole ka metastatic...E heluhelu hou aku»

Ma Iune 6, ua paʻi ka puke pai lapaʻau honua ʻo Journal of Hematology & Oncology i nā hopena noiʻi pae I/II (KL264-01/MK-2870-001) o ka TROP2 ADC sacituzumab tirumotecan (sac-TMT) hou ma ke ʻano he monotherapy no nā ʻōpū paʻa kūloko i holomua a metastatic paha i kū ʻole i ka s...E heluhelu hou aku»

Ma Iune 10, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka National Medical Products Administration (NMPA) ua manaʻo ʻia ʻo Trastuzumab Deruxtecan (T-DXd, DS-8201a) e hāʻawi ʻia i ka loiloi mua no ka mālama ʻana i nā poʻe maʻi makua me ka HER2-positive gastric o ka ʻāina holomua a i ʻole metastatic ...E heluhelu hou aku»

I kēia mau lā aku nei, ua hoʻolaha ʻo Merck & Co., Inc. (Merck) ua ʻāpono ʻia kāna mea hoʻopaʻa PD-1, ʻo pembrolizumab, e ka National Medical Products Administration (NMPA) o Kina no ka hoʻohana ʻana me ka lenvatinib a me ka transarterial chemoembolization (TACE) no ka mālama ʻana i nā maʻi me ka ʻoki ʻole ʻia...E heluhelu hou aku»